ABO血液型不適合移植の新戦略―2009―

出版社： 日本医学館
著者：
発行日： 2009-06-26
分野： 臨床医学：外科  >  移植/人工臓器
ISBN： 9784890446827
電子書籍版： 2009-06-26 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

商品紹介

本書は、第15回日本ABO血液型不適合移植研究会の主題である“ABO血液型不適合臓器移植における免疫抑制療法”の演題をとりあげた。

目次

  • ABO血液型不適合移植の新戦略―2009―

    ―目次―

    第15回日本ABO血液型不適合移植研究会
    　主題：ABO血液型不適合臓器移植における免疫抑制療法

    統計
    　1．わが国におけるABO血液型不適合腎移植の現況報告2008
    　2．ABO血液型不適合生体肝移植2008年集計報告

    REPORT　
    　坑A坑B抗体値測定における施設間格差の検討（第6報）

    腎移植
    　1．ヒト腎臓におけるABO血液型抗原を持つ蛋白質の
    　　　　プロテオーム解析
    　2．脾摘の追加で抗体関連型拒絶を克服した
    　　　　ABO血液型不適当腎移植症例
    　3．リツキシマブを用いたABO血液型不適合腎移植症例
    　4．ABO血液型不適合腎移植における
    　　　　Biosynsorb抗体吸着療法の復活
    　5．ABO血液型不適合ドナーからの生体膵・腎同時移植の成績
    　6．低抗体値症例に対する脾摘回避・坑CD20抗体
    　　　　非使用プロトコール

    肝移植
    　1．当科における成人ABO血液型不適当生体肝移植の
    　　　　門注療法を中心とした免疫抑制療法
    　2．坑血液型抗体産生B細胞の分化へのiNKT細胞の関与と
    　　　　血液型不適合臓器移植への応用の可能性
    　3．当科におけるABO血液型不適合肝移植8例の報告

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第15回日本ABO血液型不適合移植研究会 主題 : ABO血液型不適合臓器移植における免疫抑制療法

P.15 掲載の参考文献
1) Takahashi K, Saito K, Tanabe K et al.: Multicenter cooperative study group. First report of a seven-year survey on ABO-incompatible kidney transplantation in Japan. Clin Exp Nephrol 5:119-125, 2001.
 
2) Takahashi K, Saito K, Takahara S et al: Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
PubMed
3) Takahashi K, Saito K: The Japanese ABO-incompatible Kidney Transplantation Committee:present status of ABO-incompatible kidney transplantation in Japan. Xenotransplant 13:118-122, 2006.
 
4) Takahashi K: ABO-incompatible organ transplantation. Curr Opin Organ Transplant 12:409-414, 2007.
 
5) Takahashi K: Chapter 6. Accommodation in ABO-incompatible kidney transplantation-Why do kidney grafts survive? Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p37-52.
 
6) Takahashi K: A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 19 (Suppl 14) :76-85, 2005.
 
7) Takahashi K: A new immunosuppressive therapy in ABO-incompatible kidney transplantation besed on a new collcept of accommodation. ABO-incompatible organ transplantation from Japan. (ed. Takahahi K) , Elsevier, Amsterdam, 2006, p73-87.
 
8) Ogawa H, Mohiuddin MM, Galili U et al: Mouse-heart grafts expressing an incompatible carbohydrate antigen. II Transition from accommodation to tolerance. Transplantation 77:366-373, 2004.
PubMed
9) Galili U: Xenotransplantation and ABO-incompatible transplantation; the similarities they share. Transfus Apher Sci 35 :45-58, 2006.
PubMed
10) West LJ: B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation 81:301-307, 2006.
PubMed
11) Takahashi K: Chapter 8: Timing of the start of immuno-suppressive therapy (duration of desensitization therapy) . Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p94-95.
 
12) Takahashi K: ABO-incompatible kidney transplantation- Establishing a scientific framework. Elsevier, Amsterdam, 2007, p1-86.
 
13) Saito K, Nakagawa Y, Takahashi K et al.: Pinpoint targeted immunosuppression;Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplant 13:111-117, 2006.
 
14) Takahashi K: Recent fi ndings of ABO-incompatible kidney transplantation-classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-bloog group-related antigens during critical period preceding establishment of accommodation. Clin Exp Nephrol 11:128-141, 2007.
 
15) Tyden G, Kumlien G, Genberg H et al.:ABO-incompatible kidney transplantation without splenectomy using antigen-specific immunoadsorption and rituximab. Am J Transplant 5 :145-148, 2005.
PubMed
16) 高橋公太:わが国のABO血液型不適合腎移植の統計-第12回アンケート調査報告. 今日の移植 21: 578-592, 2008.
Medical*Online
17) Alexandre GPJ, Squifflet JP, Bruyere MDE et al.: Splenectomy as a prerequisite for human ABO-incompatible renal transplantation. Transplant Proc 17:138-143, 1985.
 
18) Irei T, Ohdan H, Zhou W et al.:The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110:4567-4575, 2007.
 
19) Tasaki M, Yoshida Y, Miyamoto M et al.: Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney. Transplantation 87:1125-1133, 2009.
PubMed
P.35 掲載の参考文献
1) Matsui T, Shimoyama T, Matsumoto M et al.: ABO blood group antigens on human plasma von Willebrand factor after ABO-mismatched bone marrow transplantation. Blood 4:2895-2900, 1999.
PubMed
2) Matsui T, Hamako J, Ozeki Y et al.: Comparative study of blood group-recognizing lectins toward ABO blood group antigens on neoglycoproteins, glycoproteins and complex-type oligosaccharides. Biochim Biophys Acta 1525:50-57, 2001.
PubMed
3) Finne J, Krusius T, Rauvala H et al.: Molecular nature of the blood group ABH antigens of the human erythrocyte membrane. Rev Fr Transfus Immunohematol 23:545-552, 1980.
PubMed
4) Finne J: Identification of the blood-group ABH-active glycoprotein components of human erythrocyte membrane. Eur J Biochem 104:181-189, 1980.
PubMed
5) Holgersson J, Gustafsson A, Breimer ME: Characteristics of protein--carbohydrate interactions as a basis for developing novel carbohydrate-based antirejection therapies. Immunol Cell Biol 83:694-708, 2005.
PubMed
6) Platt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FH: Endothelial cell antigens recognized by xenoreactive human natural antibodies. Transplantation 50:817-822, 1990.
PubMed
7) Holzknecht ZE, Platt JL: Identification of porcine endothelial cell membrane antigens recognized by human xenoreactive natural antibodies. J Immunol 154:4565-4575, 1995.
PubMed
8) Everett ML, Lin SS, Worrell SS et al.: The footprint of antibody bound to pig cells: evidence of complex surface topology. Biochem Biophys Res Commun 301:751-757, 2003.
PubMed
P.41 掲載の参考文献
1) Mitsuhata N, Fujita R, Ito S et al.: Splenectomy and preoperative risks in ABO incompatible kidney transplantation. Transplantation 2006, 82:719-720.
PubMed
2) Warren DS, Zachary AA, Sonnenday CJ et al.: Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004, 4:561-568.
PubMed
3) Mannami M, Mitsuhata N: Improved outcomes after ABO-incompatible living-door kidney transplantation after 4 week of treatment with mycophenolate mofetil. Transplantation 2005, 79:1756-1758.
 
4) Takahashi K, Saito K, Takahara S et al: Excellent long-term outcome of ABO-incompatible living donor kidney-transplanation in Japan. Am J Transplant 2004, 4:1089-1096.
 
5) Sonnenday CJ, Warren DS, Cooper M et al.: Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal taransplantation without splenectomy. Am J Transplant 2004, 4:1315-1322.
PubMed
6) Tyden G, Kumlien G, Genberg H et al.: ABO-incompatible kidney taransplantation without splenactomy, using antigen-specific immunoabsorption and rituximab. Am J Transplant 2005, 5:145-148.
 
7) Gloor JM. LagerDJ, Fidler ME et al: A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney taransplantation. Transplantation 2005, 80:1572-1577.
PubMed
8) Kaplan B, Gangemi A, Thielke J et al.: Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007, 83:99-100.
PubMed
9) Locke JE, Zachary AA, Haas M et al: The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007, 7:842-846.
PubMed
10) Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP: The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007, 7:402-407.
PubMed
11) Ishida H, Omoto K, Shjmizu T et a1.: Usefulness of splenectomy for chronic active antibody-mediated rejection after renal transplant. Transplant International 2008, 21: 602-604.
 
P.48 掲載の参考文献
1) Okamoto M, Omori Y, Ichida M, Nobori S, Higuchi A et al.: An autopsy case of bacterial septic shock 12 years following ABO-incompatible renal transplantation. Clin Transplant 2004, 18 (Suppl. 11):44-49.
 
2) Kaihara S, Okamoto M, Akioka K, Ogino S, Higuchi A et al.: Improved graft survival in ABO-incompatible living donor kidney transplantation. Transplant Proc 2005, 37 (4):1804-4805.
PubMed
3) 吉村了勇, 岡本雅彦, 牛込秀隆, 昇修治, 藤木真人・ 他:ABO血液型不適合腎移植におけるリツキシマブの効果と問題点. 今日の移植 2009, 22:198-203.
Medical*Online
4) Okamoto M, Omori Y, Kadotani Y, Ushigome H, Nakamura K et al.: Tacrolimus-based immunosuppression inrenal transplantation: 78 experiences in a single Japanese center. Transplant Proc 2002, 34 (5):1666.
 
5) Okamoto M, Wakabayashi Y, Higuchi A, Kadotani Y, Ogino S et al: Therapeutic drug monitoring of mycophe- nolic acid in renal transplant recipients. Transplant Proc 2005, 35:859-860.
 
6) Okamoto M, Akioka K, Higuchi A, Kadotani Y, Ushigome Het al : Clinicopathological evaluation of renal allograft treated with anti-CD25 monoclonal antibody. Clinical Transplantation 2005, 19 (Suppl. 14):49-53.
 
7) 岡本雅彦, 若林良浩, 昇修治, 樋口濃史, 荻野史朗・ 他:腎移植におけるシムレクト使用症例20例の臨床的検討. 今日の移植 2003, 16:585-586.
 
8) 岡本雅彦, 牛込秀隆, 昇修治, 吉村了勇:腎移植における免疫抑制療法の実際. 臨床検査 2008, 52(7): 773-777.
 
9) 岡本雅彦, 秋岡清一, 牛込秀隆, 荻野史朗, 門谷弥生・ 他:ABO血液型不適合腎移植における代謝拮抗剤のコンバージョンについて. Therapeutic Research 2005, 26(4):617-622.
 
10) McLaughlin P: Late-onset neutropenia following rituximab. Leuk Lymphoma 2006, 47 (6):965-966.
PubMed
11) Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F: Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003, 121 (6):913-918.
PubMed
12) Motl SE, Baskin RC: Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy 2005, 25 (8):1151-1155.
 
13) Takahashi K: Chapter 4. Why do kidney graft survive? - accommodation. ABO-incompatible kidney transplantation establish a scientific framework-. Elsevier, Amsterdam, 2007. p21-34.
 
P.54 掲載の参考文献
1) Takahashi K, Saito K, Takahara S et al: Excellent longterm outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
 
2) 高橋公太:ABO血液型不適合臓器移植における免疫学的順応のメカニズムとその誘導. ABO血液型不適合移植の新戦略2005(総集編). (高橋公太, 田中紘一・編), 日本医学館, 東京, 2005, p3-28.
 
3) Takahashi K: Accommodation in ABO-incompatible kidney transplantation. Elsevier BV, Amsterdam, 2004.
 
4) Takahashi K :A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 19 (Suppl. 14) :76-85, 2005.
 
5) Gunnar T, Gunilla K, Helena G et al.: ABO incompatible kidney transplantation without splenectomy, using antigenspecific immunoadsorption and rituximab. Am J Transplant 5:145-148, 2004.
 
6) Christopher J, Sonnenday DS, Warnen MH et al.: Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4:1315-1322, 2004.
 
7) Agishi T, Takahashi K, Ota K, Japanese Biosynsorb Research Group: immunoadosorption of anti-A or anti-B antibody for successful kidney transplantation between ABO incompatibie Pairs and its limitation. ASAIO Trans 37:496-498, 1991.
 
8) 安倍道夫:選択的血液型抗体吸着材 Biosynsorb. Clinical Engineering 2:348-353, 1991.
 
9) Helena G, Gunilla K, Lars W et al: ABO-incompatible kidney transplantation using antigen-specific immunoadosorption and rituximab: a 3-year follow-up. Am J Transplant 85:1745-1754, 2008.
 
P.61 掲載の参考文献
1) International Pancreas Transplant Registry, annual reports 2004. www. iptr. umn. edu/IPTR/annual_reports. html
 
2) 伊藤壽記, 杉谷篤, 石橋道男・他:臓器移植実施後に施行された脳死下膵腎同時移植の1症例. 移植 36:174-183, 2001.
 
3) Ishibashi M, Ito T, Furukawa H et al.: Present status of pancreas transplantation in Japan-Donation predominantly from marginal donors and modified surgical technique: Report of Japan Pancreas Transplantation Registry. Transplant Proc 40:486-490, 2008.
PubMed
4) 剣持敬, 浅野武秀, 西郷健一・他:わが国初の生体部分膵・腎同時移植の1症例. 移植 40:466-472, 2005.
Medical*Online
5) Gruessner RWG:Crossmatch positively and ABO incompatibility. Transplantation of the pancreas. (eds. Gruessner RWG, Surtherland DER) , Springer-Verlag, New York, 2004, p398-403.
 
6) 齋藤和英, 高橋公太:わが国におけるABO血液型不適合腎移植の現況報告. ABO血液型不適合移植の新戦略2008. (高橋公太, 田中紘一・編), 東京, 日本医学館, 2008, p3-17.
 
7) Kenmochi T, Saigo K, Maruyama M et al: Results of kidney transplantation from ABO-incompatible living donors in a single ins titution. Transplant Proc 40:2289-2291, 2008.
 
8) Sutherland DER, Gruessner RWG, Dunn D et al.: Pancreas transplants from living-related donors. Transplant Proc 26:443-445, 1994.
 
9) Gruessner RWG, Sutherland DER :Simultaneous kidney and segmental pancreas transplants from living related donors-the first two successful cases. Transplantation 61:1265-1268, 1996.
 
10) Gruessner RWG, Kendall DM, Drangstveit MB et al.: Simultaneous pancreas-kidney transplantation from living donors. Ann Surg 226:471-482, 1997.
 
11) Tokuyama Y, Sakurai K, Yagui K et al: Pathophysiologic phenotupes of Japanese subjects with varying degrees of glucose tolerance:Using the combination of C-peptide secretion rate and minimal model analysis. Metabolism 50:812-818, 2001.
PubMed
12) Kono T, Okazumi S, Mochizuki R et al.: Clinical application of 11C-Methionine positron emission tomography for evaluation of pancreatic function. Pancreas 25:20-25, 2002.
 
P.66 掲載の参考文献
1) 片山昭男, 打田和治, 後藤憲彦, 松岡慎, 佐藤哲彦・ 他:シクロフォスファミドを導入療法に用いたABO血液型不適合腎移植免疫抑制療法. ABO血液型不適合移植の新戦略2002. (高橋公太, 田中紘一・編), 日本医学館, 東京, 2002, p22-27.
 
2) Katayama A, Kobayashi T, Uchida K, Goto N, Matsuoka S et al: Beneficial effect of antibody removal and enhanced immunosupPression in flow cytometry cross match-positive and ABO incompatible renal transplantation. Transplantation Proceedings 34:2771-2772 , 2002.
PubMed
3) 片山昭男, 打田和治, 後藤憲彦, 松岡慎, 佐藤哲彦・ 他:ABO血液型不適合生体腎移植免疫抑制療法- Basiliximab induction. カリシニューリンインヒビターAUCモニタリングによるクリニカルパス導入症例を中心に-. ABO血液型不適合移植の新戦略2007. (高橋公太, 田中紘一・編), 日本医学館, 東京, 2002, p81-86.
 
4) 片山昭男, 平光高久, 後藤憲彦, 佐藤哲彦, 長坂隆治, 渡井至彦, 打田和治・他:ABO血液型不適合腎移植における血液型抗体対策の簡略化-術前低抗体価症例に対する脾摘回避・リツキシマブ非使用プロトコールの経験-. ABO血液型不適合移植の新戦略2008. (高橋公太, 田中紘一・編), 日本医学館, 東京, 2008, p64-69.
 
P.71 掲載の参考文献
1) Demetris AJ, Jaffe R, Tzakis A et al: Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 132:489-502, 1988.
PubMed
2) Egawa H, Oike F, Buhler L et al.: Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 77:403-411, 2004.
PubMed
3) Tanabe M, Shimazu M, Wakabayashi G et al.: Intra-portal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.
 
P.76 掲載の参考文献
1) Zhou W, Ohdan H, Tanaka Y, Hara H, Tokita D et al.: NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol 12 (1):9-18, 2003.
PubMed
2) Lang GA, Exley MA, Lang ML: The CD1d-binding glycolipid α-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology 119 (1):116-25, 2006.
 
3) Irei T, Ohdan H, Zhou W, Ishiyama K, Tanaka Y et al.: The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept inpreventing antibody-mediated rejection in ABO-incompatible transplantation、 Blood 110 (13):4567-4575, 2007.
 
4) Snapper CM, Mond JJ: A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J Immunol 157 (6):2229-2233, 1996.
 
5) Kitamura H, Ohta A, Sekimoto M, Sato M, Iwakabe K et al: α-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol 199 (1):37-42, 2000.
 
6) Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y et al.: Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 104 (10):3984-3989, 2007.
PubMed
7) Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C et al.: CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 197 (8):1051-1057, 2003.
 
8) Campos RA, Szczepanik M, Itakura A, Akahira-Azuma M, Sidobre S et al.: Cutaneous immunization rapidly activates liver invariant Valpha14NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity. J Exp Med 198 (12):1785-1796, 2003.
 
9) Ohdan H, Swenson KG, Kruger Gray HS, Yang YG, Xu Y et al.: Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1, 3 Gal epitopes in alpha l, 3-galactosyltransferase-deficient mice. J Immunol 165 (10):5518-5529, 2000.
 
P.83 掲載の参考文献
1) Ohdan H et al: Evidence of immune tolerance to blood group antigens in a case of ABO-incompatible pediatric liver transplantation. Am J Transplant 7（9):2190-2194, 2007.
 
2) Irei T et al.: The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110 (13):4567-4575, 2007.
 

書評

最近チェックした商品履歴

Loading...